A new machine-learning approach for prostate-specific membrane antigen (PSMA) treatment of metastatic castration-resistant prostate cancer (mCRPC) could estimate radiation dose to tumors and healthy organs before therapy ...
May 30, 2026
0
6
Ceramides—lipid molecules in cells that affect many physiological functions including cell differentiation, migration, and death—and their metabolites have been implicated in the development of cancer and other conditions. ...
May 26, 2026
0
6
Researchers with the James P. Allison Institute at The University of Texas MD Anderson Cancer Center have discovered a new gene expression signature within tumors that can help identify patients with metastatic castration-resistant ...
May 21, 2026
0
8
For men with advanced prostate cancer that no longer responds to standard hormone therapies, treatment options are limited—and time matters. As the disease progresses, the window for effective, less intensive treatments begins ...
May 15, 2026
0
13
Northwestern Medicine scientists have discovered that a specific long non-coding RNA activates oncogenic signaling pathways in prostate cancer cells and drives tumor progression, underscoring its potential as a therapeutic ...
Apr 9, 2026
0
8
A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that androgen receptor (AR) alterations consistently emerged and were linked to poorer outcomes across ...
Feb 26, 2026
0
11
A common clinical question for medical oncologists treating metastatic castration-resistant prostate cancer is, should patients who previously received docetaxel and progress on it, reuse docetaxel or switch to cabazitaxel ...
Feb 18, 2026
0
5
Data from a major U.S. clinical trial from the Alliance for Clinical Trials in Oncology has uncovered a genetic factor that may inform how to optimize the dosing of abiraterone, a widely used hormone treatment for advanced ...
Jan 15, 2026
0
11
A new fast and convenient approach to scintigraphy-based monitoring allows physicians to efficiently and reliably assess prostate cancer progression or regression during treatment. With this strong prognostic information, ...
Oct 16, 2025
0
16
For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR) gene alterations, talazoparib (TALA) + enzalutamide (ENZA) is associated with improved overall ...
Feb 19, 2025
0
18
